Mercado mundial de fibrosis hepática: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de la fibrosis hepática crezca rápidamente durante el período de pronóstico. Según el estudio de 2019 "Carga de enfermedades hepáticas en el mundo", la enfermedad hepática causa aproximadamente 2 millones de muertes en todo el mundo, con 1 millón de muertes debido a complicaciones de cirrosis y 1 millón de muertes debido a hepatitis viral y cáncer hepatocelular. Los profesionales de la salud se concentran en el tratamiento de la fibrosis hepática abordando la causa subyacente de la enfermedad para prevenir o retrasar la cicatrización del hígado. El consumo crónico de alcohol, la hepatitis autoinmune, los trastornos de almacenamiento y metabolismo como la enfermedad de Wilson, la galactosemia, la fructosemia, las enfermedades de almacenamiento de glucógeno, los síntomas de sobrecarga de hierro, la enfermedad de Gaucher, las infecciones bacterianas, parasitarias y virales y los trastornos que afectan el flujo sanguíneo hepático, entre otros, son todos posibles factores de riesgo para el manejo de la fibrosis hepática.

Data Bridge Market Research analiza que el mercado de la fibrosis hepática se valoró en USD 16,45 mil millones en 2021 y se espera que alcance los USD 38,74 mil millones para 2029, registrando una CAGR del 11,30% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Definición de mercado

El daño hepático repetido o persistente da como resultado una cantidad inusualmente alta de tejido cicatricial en el hígado, lo que se conoce como fibrosis hepática. La fibrosis no presenta síntomas, pero la cicatrización extensa causa cirrosis , que provoca síntomas. Los proveedores de atención médica utilizan análisis de sangre y de diagnóstico por imágenes para determinar la gravedad de la afección, y una biopsia hepática. Los profesionales de la salud se centran en tratar la fuente de la fibrosis hepática, lo que a menudo detiene o ralentiza la cicatrización adicional del hígado y conduce a un mejor resultado. Los medicamentos antivirales y la eliminación o disolución de una obstrucción en los conductos biliares son todos tratamientos potenciales para la fibrosis hepática.

Alcance del informe y segmentación del mercado

Dinámica del mercado de la fibrosis hepática

Conductores

• Aumento de la prevalencia de fibrosis hepática

Se estima que la creciente prevalencia de la fibrosis hepática en todo el mundo impulsará el crecimiento del mercado. Junto con esto, se prevé que la creciente prevalencia de factores de riesgo como la infección crónica por hepatitis B o C, un sistema inmunológico debilitado debido a la coinfección por VIH o el uso de medicamentos inmunosupresores después de un trasplante de hígado impulsarán el mercado de la fibrosis hepática.

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la fibrosis hepática es el aumento del gasto sanitario, que ayuda a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

• Creciente número de población geriátrica

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to liver fibrosis, further estimated to enhance the 'market's growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the liver fibrosis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and rising disposable income will result in the expansion of liver fibrosis market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the liver fibrosis market growth. Along with this, rising drug approvals and launches will further propel the 'market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the liver fibrosis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the liver fibrosis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This liver fibrosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the liver fibrosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Liver fibrosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Liver Fibrosis Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the liver fibrosis market.

Recent Development

• In January 2022, Siemens Healthineers announced the launch of the Enhanced Liver Fibrosis (ELF) Test in the U.S. this test offers broad clinical access to the minimally invasive prognostic tool. The ELF Test is a simple, efficient blood test for determining prognosis in individuals with advanced fibrosis (F3 or F4) caused by non-alcoholic steatohepatitis (NASH), a kind of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation.

Global Liver Fibrosis Market Scope

The liver fibrosis market is segmented on the basis of condition, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Condition

• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis

Route of Administration

• Oral
• Parenteral
• Others

Diagnosis

• Nonsurgical Tests
• Transient Elastography
• Liver Biopsy
• Others

Treatment

• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
• Hepatotropic Drug
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Liver Fibrosis Market Regional Analysis/Insights

The liver fibrosis market is analysed and market size insights and trends are provided by country, condition, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the liver fibrosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the liver fibrosis market because of the presence of variety of innovative drug molecule to enhance the treatment procedure and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the 'market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing prevalence of liver disorders in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Liver Fibrosis Market Share Analysis

The liver fibrosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to liver fibrosis market.

Some of the major players operating in the liver fibrosis market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (US)
• Bristol-Myers Squibb Company (US)
• Gilead Sciences, Inc. (US)
• Vertex Pharmaceuticals Incorporated (US)
• FibroGen, Inc. (US)
• Pharmaxis Ltd (Australia)
• Dicerna Pharmaceuticals, Inc. (Estados Unidos)
• Dynavax Technologies (Estados Unidos)

SKU-54747